Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study

Qaiser Bashir; Mark Acosta

doi:10.1016/j.clml.2020.06.022

Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study

Qaiser Bashir
, Mark Acosta

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Patients with multiple myeloma often receive dexamethasone in combination with novel agent treatment. The current study compared the rate and extent of absorption of a single 20-mg dexamethasone tablet to five 4-mg tablets (total, 20 mg). Both formulations were well-tolerated and bioequivalent under fasting conditions, and dexamethasone 20-mg tablet under fed conditions demonstrated comparable total exposure to fasted conditions.

Original language	English (US)
Pages (from-to)	768-773
Number of pages	6
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.clml.2020.06.022
State	Published - Nov 2020

Keywords

Bioavailability
Corticosteroids
Dexamethasone
Myeloma
Oral formulation

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2020.06.022

Fingerprint

Dive into the research topics of 'Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study'. Together they form a unique fingerprint.

Cite this

Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study. / Bashir, Qaiser; Acosta, Mark.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, No. 11, 11.2020, p. 768-773.

Research output: Contribution to journal › Article › peer-review

@article{c207895c217e4098b7d1845a534b3d2b,

title = "Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study",

abstract = "Patients with multiple myeloma often receive dexamethasone in combination with novel agent treatment. The current study compared the rate and extent of absorption of a single 20-mg dexamethasone tablet to five 4-mg tablets (total, 20 mg). Both formulations were well-tolerated and bioequivalent under fasting conditions, and dexamethasone 20-mg tablet under fed conditions demonstrated comparable total exposure to fasted conditions.",

keywords = "Bioavailability, Corticosteroids, Dexamethasone, Myeloma, Oral formulation",

author = "Qaiser Bashir and Mark Acosta",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = nov,

doi = "10.1016/j.clml.2020.06.022",

language = "English (US)",

volume = "20",

pages = "768--773",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions

T2 - A Randomized Open-label, 3-way Crossover Study

AU - Bashir, Qaiser

AU - Acosta, Mark

PY - 2020/11

Y1 - 2020/11

N2 - Patients with multiple myeloma often receive dexamethasone in combination with novel agent treatment. The current study compared the rate and extent of absorption of a single 20-mg dexamethasone tablet to five 4-mg tablets (total, 20 mg). Both formulations were well-tolerated and bioequivalent under fasting conditions, and dexamethasone 20-mg tablet under fed conditions demonstrated comparable total exposure to fasted conditions.

AB - Patients with multiple myeloma often receive dexamethasone in combination with novel agent treatment. The current study compared the rate and extent of absorption of a single 20-mg dexamethasone tablet to five 4-mg tablets (total, 20 mg). Both formulations were well-tolerated and bioequivalent under fasting conditions, and dexamethasone 20-mg tablet under fed conditions demonstrated comparable total exposure to fasted conditions.

KW - Bioavailability

KW - Corticosteroids

KW - Dexamethasone

KW - Myeloma

KW - Oral formulation

UR - https://www.scopus.com/pages/publications/85090490181

UR - https://www.scopus.com/pages/publications/85090490181#tab=citedBy

U2 - 10.1016/j.clml.2020.06.022

DO - 10.1016/j.clml.2020.06.022

M3 - Article

C2 - 32900662

AN - SCOPUS:85090490181

SN - 2152-2650

VL - 20

SP - 768

EP - 773

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 11

ER -

Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this